查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1474866

小分子創新者 API CDMO 市場規模、佔有率、趨勢分析報告：按階段類型、客戶類型、治療領域、地區、細分市場預測，2024-2030 年

Small Molecule Innovator API CDMO Market Size, Share & Trends Analysis Report By Stage Type (Preclinical, Clinical, Commercial), By Customer Type, By Therapeutic Area, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 241 Pages | 商品交期: 2-10個工作天內

價格

小分子創新者 API CDMO 市場成長與趨勢：

根據 Grand View Research, Inc. 的最新報告，預計到 2030 年，全球小分子創新藥 API CDMO 市場規模將達到 471.4 億美元，2024 年至 2030 年複合年成長率為 6.53%。

製藥公司外包趨勢的上升、小分子藥物需求的增加以及臨床試驗數量的快速增加預計將對市場產生積極影響。製藥業越來越多使用 CDMO 的原因有很多，其中成本效益是一個突出因素。外包已成為製藥公司透過避免昂貴的基礎設施和資本投資來減少開支的有效策略。 CDMO 提供必要的專業知識和基礎設施，以在財務上審慎的方式提供藥物開發和製造服務。

此外，提高效率也是製藥外包的關鍵驅動力。隨著製藥公司面臨更快將新藥推向市場的壓力，外包已成為加速藥物開發過程的解決方案。 CDMO 利用其專業知識、經驗和最先進的設備來促進高品質藥品的快速高效生產，並使製藥公司能夠滿足開發進度。此外，隨著新療法和孤兒藥的不斷湧入，以及已通過核准產品收益的增加，一些製藥公司正在選擇 CDMO 來利用先進的基礎設施和專業知識。此外，CDMO 持續的技術進步提供了創新的小分子原料藥，可以滿足醫療產業對創新、效率和監管合規性日益成長的需求。

當公司採用先進技術時，他們可以改善藥物開發、製造流程和生產力。製藥業對新型小分子創新 API 的需求不斷成長，正在推動商業 CDMO 產能擴張，預計將推動市場成長。例如，2023年8月，Astex宣布與默沙東達成合作研究和授權合約，將小分子候選物與腫瘤抑制蛋白一起分類，用於癌症治療。根據協議，該公司將利用其基於片段的藥物發現平台開發化合物，並向默沙東提供先導化合物以進行臨床前開發和最佳化。

小分子創新者 API CDMO 市場報告亮點

  • 2023年，臨床階段細分市場佔據市場主導地位，佔有率為54.68%。該領域的成長是由於各種製劑的臨床試驗（I-III 期）活動的增加、小分子開發平臺的擴大、專業知識的可用性的增加以及創新帶來的縮短時間且更具成本效益的臨床實驗藥物開發所活性化的。此外，資金籌措也支持該產業的成長。
  • 按客戶類型分類，由於先進藥物開發的藥物研發快速進步，製藥領域在 2023 年佔據最大佔有率。此外，各種治療方法的進步已將製藥公司的 CDMO 重點轉向開發新型小分子創新 API 藥物來治療多種疾病。
  • 癌症治療領域佔據市場主導地位，2023年佔42.25%的佔有率。全球癌症發生率的上升推動了這一領域的發展。此外，對創新小分子創新原料藥的需求不斷增加、標靶治療的進步以及對癌症藥物創新的需求是推動癌症治療領域的因素。
  • 由於慢性病盛行率不斷上升、對小分子原料藥和 CDMO 服務的需求以及醫療基礎設施的改善，亞太地區在 2023 年將佔據市場佔有率 41.53%。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第 3 章 小分子創新者 API CDMO 市場變數、趨勢與範圍

  • 市場體系展望
  • 市場動態
  • 技術景觀
  • 按階段和地區分類的臨床試驗總數（2021-2023）
  • 小分子創新者 API CDMO 市場：分析工具
  • COVID-19 對小分子創新者 API CDMO 市場的影響
  • COVID-19 影響分析

第4章小分子創新者 API CDMO 市場：階段類型估計與趨勢分析

  • 細分儀表板
  • 全球小分子創新藥API CDMO市場波動分析
  • 2018-2030 年全球小分子創新 API CDMO 市場規模及趨勢分析（依階段類型）

第5章小分子創新者 API CDMO 市場：客戶類型估計與趨勢分析

  • 細分儀表板
  • 全球小分子創新藥API CDMO市場波動分析
  • 2018-2030年全球小分子創新藥物API CDMO市場規模與趨勢分析（依顧客類型）

第6章小分子創新者API CDMO市場：治療領域的估計與趨勢分析

  • 定義和範圍
  • 2023 年和 2030 年治療領域市場佔有率
  • 細分儀表板
  • 全球小分子創新藥API CDMO市場波動分析
  • 2018-2030 年全球小分子創新藥物 API CDMO 市場規模與趨勢分析（依治療領域）

第 7 章 小分子創新者 API CDMO 市場：區域估計與趨勢分析

  • 區域市場儀表板
  • 全球區域市場概述
  • 2018-2030年市場規模、預測趨勢分析：
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東/非洲

第8章 競爭格局

  • 市場參與企業分類
  • 服務熱力圖分析（玩家間比較分析）
  • 公司簡介
  • 供應商情況
    • Key company market share analysis, 2023
    • Lonza Group Ltd.
    • Novo Holdings（Catalent, Inc.）
    • Thermo Fisher Scientific, Inc.
    • Siegfried Holding AG
    • Recipharm AB
    • CordenPharma International
    • Samsung Biologics
    • Labcorp
    • Ajinomoto Bio-Pharma Services
    • Piramal Pharma Solutions
    • Jubilant Life Sciences（Jubilant Biosys Limited）
    • WuXi AppTec Co., Ltd.
Product Code: GVR-4-68040-250-0

Small Molecule Innovator API CDMO Market Growth & Trends:

The global small molecule innovator API CDMO market size is expected to reach USD 47.14 billion by 2030, registering a CAGR of 6.53% from 2024 to 2030, according to a new report by Grand View Research, Inc. A growing outsourcing trend among pharmaceutical companies, increasing demand for small molecule drugs, and a surge in the number of clinical trials are anticipated to influence the market positively. The growing utilization of CDMOs in the pharmaceutical sector stems from various reasons, with cost-effectiveness as the prominent factor. Outsourcing emerges as an efficient strategy for pharmaceutical firms to reduce expenses by sidestepping the necessity for costly infrastructure and equipment investments. CDMOs offer the requisite expertise and infrastructure to deliver drug development and manufacturing services in a financially prudent manner.

Furthermore, enhanced efficiency serves as another pivotal driver for pharmaceutical outsourcing. With mounting pressure on pharmaceutical companies to expedite the introduction of new drugs to the market, outsourcing emerges as a solution to accelerate the drug development process. Leveraging their expertise, experience, and cutting-edge equipment, CDMOs facilitate the swift & efficient production of high-quality drugs, enabling pharmaceutical firms to adhere to their development schedules. In addition, several pharmaceutical companies prefer CDMOs to access advanced infrastructure and expertise due to the increasing influx of novel therapies & orphan drugs and higher returns on approved products. Moreover, continuous technological advancements among CDMOs offer innovative small molecule APIs to meet the growing demands for innovation, efficiency, and regulatory compliance in the healthcare industry.

The adoption of advanced technologies by companies enhances drug development, manufacturing processes, and productivity. The increasing demand for new small molecule innovator API in the pharmaceutical industry is encouraging commercial CDMOs to expand their capabilities, which is expected to boost market growth. For instance, in August 2023, Astex announced a research collaboration & license agreement with MSD to classify small molecule candidates with tumor suppressor proteins for cancer treatment. Under the agreement, the company will use its fragment-based drug discovery platform to develop compounds and provide MSD with main compounds for preclinical development & optimization.

Small Molecule Innovator API CDMO Market Report Highlights:

  • The clinical stage type segment dominated the market with a share of 54.68% in 2023. Growth in the segment can be attributed to the rising clinical trial (phase I-III) activities for diverse formulations, growing small molecule development pipeline, increasing availability of specialized expertise, timesaving & cost-efficiency for investigational drugs, and innovations. Moreover, rising funding for drug development is propelling segment growth
  • Based on the customer type, the pharmaceutical segment held the largest share in 2023 due to rapid advancements in pharmaceutical R&D for the development of advanced drugs. In addition, advancements in various therapies have shifted pharmaceutical companies' focus on CDMOs to developing novel small molecule innovator API drugs to treat numerous diseases
  • The oncology therapeutic area segment dominated the market and accounted for a share of 42.25% in 2023. The segment growth is driven by the increasing prevalence of cancer globally. In addition, growing demand for innovative small molecule innovator APIs, advancements in targeted therapies, and demand for oncology drugs innovations are the factors driving the oncology segment
  • Asia Pacific dominated the market with a share of 41.53% in 2023 due to increasing prevalence of chronic diseases, demand for small molecule APIs & CDMO services, and improving healthcare infrastructure

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Regional Scope
    • 1.1.2. Estimates and Forecast Timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased Database
    • 1.3.2. GVR's Internal Database
    • 1.3.3. Secondary Sources
    • 1.3.4. Primary Research
    • 1.3.5. Details of Primary Research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data Analysis Models
  • 1.5. Market Formulation & Validation
    • 1.5.1. Region Wise Market: Base Estimates
    • 1.5.2. Global Market: CAGR Calculation
  • 1.6. Model Details
    • 1.6.1. Commodity Flow Analysis (Model 1)
    • 1.6.2. Value-Chain-Based Sizing & Forecasting (Model 2)
    • 1.6.3. QFD Model Sizing & Forecasting (Model 3)
    • 1.6.4. Bottom-Up Approach (Model 4)
  • 1.7. Market Definitions
  • 1.8. List of Secondary Sources
  • 1.9. List of Abbreviations
  • 1.10. Objectives
    • 1.10.1. Objective - 1
    • 1.10.2. Objective - 2
    • 1.10.3. Objective - 3
    • 1.10.4. Objective - 4

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Small Molecule Innovator API CDMO Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Ancillary Market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing Demand for Small Molecule Drugs
      • 3.2.1.2. Increasing Outsourcing Trends Among Pharmaceutical Companies
      • 3.2.1.3. Surge in Number of Clinical Trials
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Compliance Issues While Outsourcing
      • 3.2.2.2. Changing Scenarios in Developing Economies
  • 3.3. Technology Landscape
    • 3.3.1. Integration Of Ai In Small Molecule Innovator API CDMO Market
      • 3.3.1.1. Current Dynamics and Future Trends
      • 3.3.1.1.1. Drug Discovery and Design
      • 3.3.1.1.2. AI-Assisted Drug API Synthesis
      • 3.3.1.1.3. Process Optimization
      • 3.3.1.1.4. Supply Chain Management
      • 3.3.1.1.5. Clinical Trial Optimization
      • 3.3.1.1.6. Regulatory Compliance
  • 3.4. Total Number of Clinical Trials by Phase & Region (2021 - 2023)
    • 3.4.1. Total Number of Clinical Trials by Phase (2021 - 2023)
    • 3.4.2. Total Number of Clinical Trials by Region (2021 - 2023)
      • 3.4.2.1. Percentage of Clinical Trials by Major Countries in North America:
      • 3.4.2.2. Percentage of Clinical Trials by Major Countries in Europe:
      • 3.4.2.3. Percentage of Clinical Trials by Major Countries in Asia Pacific:
      • 3.4.2.4. Percentage of Clinical Trials by Major Countries in Latin America:
      • 3.4.2.5. Percentage of Clinical Trials by Major Countries in the Middle East & Africa:
    • 3.4.3. Total Number of Clinical Trials by Therapeutic Area (2021 - 2023)
  • 3.5. Small Molecule Innovator API CDMO Market: Analysis Tools
    • 3.5.1. Porter's Five Forces Analysis
    • 3.5.2. PESTEL Analysis
  • 3.6. Impact of COVID-19 on Small Molecule Innovator CDMO Market
  • 3.7. COVID-19 Impact Analysis

Chapter 4. Small Molecule Innovator API CDMO Market: Stage Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Small Molecule Innovator API CDMO Market Movement Analysis
  • 4.3. Global Small Molecule Innovator API CDMO Market Size & Trend Analysis, by Stage Type, 2018 to 2030 (USD Million)
    • 4.3.1. Preclinical
      • 4.3.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 4.3.2. Clinical
      • 4.3.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
      • 4.3.2.2. Phase I
      • 4.3.2.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
      • 4.3.2.3. Phase II
      • 4.3.2.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
      • 4.3.2.4. Phase III
      • 4.3.2.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 4.3.3. Commercial
      • 4.3.3.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 5. Small Molecule Innovator API CDMO Market: Customer Type Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Small Molecule Innovator API CDMO Market Movement Analysis
  • 5.3. Global Small Molecule Innovator API CDMO Market Size & Trend Analysis, by Customer Type, 2018 to 2030 (USD Million)
    • 5.3.1. Pharmaceutical
      • 5.3.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
      • 5.3.1.2. Small
      • 5.3.1.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
      • 5.3.1.3. Medium
      • 5.3.1.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
      • 5.3.1.4. Large
      • 5.3.1.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 5.3.2. Biotechnology
      • 5.3.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
      • 5.3.2.2. Small
      • 5.3.2.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
      • 5.3.2.3. Medium
      • 5.3.2.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
      • 5.3.2.4. Large
      • 5.3.2.4.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 6. Small Molecule Innovator API CDMO Market: Therapeutic Area Estimates & Trend Analysis

  • 6.1. Definitions and Scope
    • 6.1.1. Cardiovascular Diseases
    • 6.1.2. Oncology
    • 6.1.3. Respiratory Disorders
    • 6.1.4. Neurology
    • 6.1.5. Metabolic Disorders
    • 6.1.6. Infectious Diseases
    • 6.1.7. Others
  • 6.2. Therapeutic Area Market Share, 2023 & 2030
  • 6.3. Segment Dashboard
  • 6.4. Global Small Molecule Innovator API CDMO Market Movement Analysis
  • 6.5. Global Small Molecule Innovator API CDMO Market Size & Trend Analysis, by Therapeutic Area, 2018 to 2030 (USD Million)
    • 6.5.1. Cardiovascular Diseases
      • 6.5.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 6.5.2. Oncology
      • 6.5.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 6.5.3. Respiratory Disorders
      • 6.5.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 6.5.4. Neurology
      • 6.5.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 6.5.5. Metabolic Disorders
      • 6.5.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 6.5.6. Infectious Diseases
      • 6.5.6.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 6.5.7. Others
      • 6.5.7.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 7. Small Molecule Innovator API CDMO Market: Regional Estimates & Trend Analysis by Product, Workflow, & Application

  • 7.1. Regional Market Dashboard
  • 7.2. Global Regional Market Snapshot
  • 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.4. North America
    • 7.4.1. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. Regulatory Scenario
      • 7.4.2.4. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. Regulatory Scenario
      • 7.4.3.4. Market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Regulatory Scenario
      • 7.5.2.4. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. Regulatory Scenario
      • 7.5.3.4. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Competitive Scenario
      • 7.5.4.3. Regulatory Scenario
      • 7.5.4.4. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Competitive Scenario
      • 7.5.5.3. Regulatory Scenario
      • 7.5.5.4. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Competitive Scenario
      • 7.5.6.3. Regulatory Scenario
      • 7.5.6.4. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Competitive Scenario
      • 7.5.7.3. Regulatory Scenario
      • 7.5.7.4. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Competitive Scenario
      • 7.5.8.3. Regulatory Scenario
      • 7.5.8.4. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Competitive Scenario
      • 7.5.9.3. Regulatory Scenario
      • 7.5.9.4. Market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.6.2. China
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. Regulatory Scenario
      • 7.6.2.4. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.6.3. Japan
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Regulatory Scenario
      • 7.6.3.4. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Competitive Scenario
      • 7.6.4.3. Regulatory Scenario
      • 7.6.4.4. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Competitive Scenario
      • 7.6.5.3. Regulatory Scenario
      • 7.6.5.4. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.6.6. South Korea
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Competitive Scenario
      • 7.6.6.3. Regulatory Scenario
      • 7.6.6.4. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Competitive Scenario
      • 7.6.7.3. Regulatory Scenario
      • 7.6.7.4. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.6.8. Taiwan
      • 7.6.8.1. Key Country Dynamics
      • 7.6.8.2. Competitive Scenario
      • 7.6.8.3. Regulatory Scenario
      • 7.6.8.4. Market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Competitive Scenario
      • 7.7.2.3. Regulatory Scenario
      • 7.7.2.4. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.7.3. Mexico
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Competitive Scenario
      • 7.7.3.3. Regulatory Scenario
      • 7.7.3.4. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.7.4. Argentina
      • 7.7.4.1. Key Country Dynamics
      • 7.7.4.2. Competitive Scenario
      • 7.7.4.3. Regulatory Scenario
      • 7.7.4.4. Market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.8. MEA
    • 7.8.1. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Competitive Scenario
      • 7.8.2.3. Regulatory Scenario
      • 7.8.2.4. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Competitive Scenario
      • 7.8.3.3. Regulatory Scenario
      • 7.8.3.4. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Competitive Scenario
      • 7.8.4.3. Regulatory Scenario
      • 7.8.4.4. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Competitive Scenario
      • 7.8.5.3. Regulatory Scenario
      • 7.8.5.4. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.8.6. Israel
      • 7.8.6.1. Key Country Dynamics
      • 7.8.6.2. Competitive Scenario
      • 7.8.6.3. Regulatory Scenario
      • 7.8.6.4. Market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Market Participant Categorization
  • 8.2. Service Heat Map Analysis (a comparative analysis of the players together)
  • 8.3. Company Profiles
  • 8.4. Company Profiles
    • 8.4.1. Strategy Mapping
    • 8.4.2. Expansion
    • 8.4.3. Partnerships
    • 8.4.4. Acquisitions
  • 8.5. Vendor Landscape
    • 8.5.1. Key company market share analysis, 2023
    • 8.5.2. Lonza Group Ltd.
      • 8.5.2.1. Company overview
      • 8.5.2.2. Financial performance
      • 8.5.2.3. Product/service benchmarking
      • 8.5.2.4. Strategic initiatives
    • 8.5.3. Novo Holdings (Catalent, Inc.)
      • 8.5.3.1. Company overview
      • 8.5.3.2. Financial performance
      • 8.5.3.3. Product/service benchmarking
      • 8.5.3.4. Strategic initiatives
    • 8.5.4. Thermo Fisher Scientific, Inc.
      • 8.5.4.1. Company overview
      • 8.5.4.2. Financial performance
      • 8.5.4.3. Product/service benchmarking
      • 8.5.4.4. Strategic initiatives
    • 8.5.5. Siegfried Holding AG
      • 8.5.5.1. Company overview
      • 8.5.5.2. Financial performance
      • 8.5.5.3. Product/service benchmarking
      • 8.5.5.4. Strategic initiatives
    • 8.5.6. Recipharm AB
      • 8.5.6.1. Company overview
      • 8.5.6.2. Financial performance
      • 8.5.6.3. Product/service benchmarking
      • 8.5.6.4. Strategic initiatives
    • 8.5.7. CordenPharma International
      • 8.5.7.1. Company overview
      • 8.5.7.2. Financial performance
      • 8.5.7.3. Product/service benchmarking
      • 8.5.7.4. Strategic initiatives
    • 8.5.8. Samsung Biologics
      • 8.5.8.1. Company overview
      • 8.5.8.2. Financial performance
      • 8.5.8.3. Product/service benchmarking
      • 8.5.8.4. Strategic initiatives
    • 8.5.9. Labcorp
      • 8.5.9.1. Company overview
      • 8.5.9.2. Financial performance
      • 8.5.9.3. Product/service benchmarking
      • 8.5.9.4. Strategic initiatives
    • 8.5.10. Ajinomoto Bio-Pharma Services
      • 8.5.10.1. Company overview
      • 8.5.10.2. Financial performance
      • 8.5.10.3. Product/service benchmarking
      • 8.5.10.4. Strategic initiatives
    • 8.5.11. Piramal Pharma Solutions
      • 8.5.11.1. Company overview
      • 8.5.11.2. Financial performance
      • 8.5.11.3. Product/service benchmarking
      • 8.5.11.4. Strategic initiatives
    • 8.5.12. Jubilant Life Sciences (Jubilant Biosys Limited)
      • 8.5.12.1. Company overview
      • 8.5.12.2. Financial performance
      • 8.5.12.3. Product/service benchmarking
      • 8.5.12.4. Strategic initiatives
    • 8.5.13. WuXi AppTec Co., Ltd.
      • 8.5.13.1. Company overview
      • 8.5.13.2. Financial performance
      • 8.5.13.3. Product/service benchmarking
      • 8.5.13.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America Small Molecule Innovator API CDMO market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 4 North America Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 5 North America Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 6 U.S. Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 7 U.S. Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 8 U.S. Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 9 Canada Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 10 Canada Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 11 Canada Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 12 Europe Small Molecule Innovator API CDMO market, by region, 2018 - 2030 (USD Million)
  • Table 13 Europe Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 14 Europe Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 15 Europe Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 16 UK Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 17 UK Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 18 UK Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 19 Germany Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 20 Germany Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 21 Germany Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 22 France Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 23 France Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 24 France Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 25 Italy Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 26 Italy Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 27 Italy Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 28 Spain Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 29 Spain Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 30 Spain Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 31 Denmark Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 32 Denmark Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 33 Denmark Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 34 Sweden Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 35 Sweden Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 36 Sweden Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 37 Norway Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 38 Norway Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 39 Norway Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific Small Molecule Innovator API CDMO market, by region, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 44 China Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 45 China Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 46 China Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 47 Japan Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 48 Japan Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 49 Japan Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 50 India Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 51 India Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 52 India Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 53 Australia Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 54 Australia Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 55 Australia Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 56 South Korea Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 57 South Korea Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 58 South Korea Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 59 Thailand Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 60 Thailand Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 61 Thailand Taiwan Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 62 Taiwan Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 63 Taiwan Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 64 Taiwan Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 65 Latin America Small Molecule Innovator API CDMO market, by region, 2018 - 2030 (USD Million)
  • Table 66 Latin America Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 67 Latin America Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 68 Latin America Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 69 Brazil Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 70 Brazil Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 71 Brazil Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 72 Mexico Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 73 Mexico Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 74 Mexico Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 75 Argentina Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 76 Argentina Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 77 Argentina Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 78 MEA Small Molecule Innovator API CDMO market, by region, 2018 - 2030 (USD Million)
  • Table 79 MEA Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 80 MEA Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 81 MEA Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 82 South Africa Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 83 South Africa Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 84 South Africa Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 85 Saudi Arabia Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 86 Saudi Arabia Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 88 UAE Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 89 UAE Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 90 UAE Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 91 Kuwait Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 92 Kuwait Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 93 Kuwait Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 94 Israel Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
  • Table 95 Israel Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
  • Table 96 Israel Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Small molecule innovator API CDMO market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Market formulation & validation
  • Fig. 7 Commodity flow analysis
  • Fig. 8 Value-Chain-Based Sizing & Forecasting
  • Fig. 9 QFD model sizing & forecasting
  • Fig. 10 Bottom-up approach
  • Fig. 11 Market snapshot
  • Fig. 12 Segment snapshot
  • Fig. 13 Segment snapshot
  • Fig. 14 Competitive landscape snapshot
  • Fig. 15 Parent market outlook, 2023(USD Million)
  • Fig. 16 Ancillary market outlook, 2023 (USD Million)
  • Fig. 17 Small molecule innovator API CDMO market dynamics
  • Fig. 18 FDA's novel drug approvals in 2023
  • Fig. 19 Percentage of clinical trials by major countries in North America
  • Fig. 20 Percentage of clinical trials by major countries in Europe
  • Fig. 21 Percentage of clinical trials by major countries in Asia Pacific
  • Fig. 22 Percentage of clinical trials by major countries in Latin America
  • Fig. 23 Percentage of clinical trials by major countries in Middle East & Africa
  • Fig. 24 Porter's five forces analysis
  • Fig. 25 Small molecule innovator API CDMO market: PESTEL analysis
  • Fig. 26 Small molecule innovator API CDMO market: Stage Type outlook and key takeaways
  • Fig. 27 Small molecule innovator API CDMO market: Stage type movement analysis
  • Fig. 28 Preclinical small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Clinical small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Phase I small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Phase II small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Phase III small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Commercial small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 Small molecule innovator API CDMO market: Customer type outlook and key takeaways
  • Fig. 35 Small molecule innovator API CDMO market: Customer type movement analysis
  • Fig. 36 Pharmaceutical small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Small pharmaceutical customer in small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Medium pharmaceutical customer in small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 39 Large pharmaceutical customer in small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 40 Biotechnology small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 41 Small biotechnology customer in small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 42 Medium biotechnology customer in small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 43 Large biotechnology customer in small molecule molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 44 Small molecule innovator API CDMO market: Therapeutic area outlook and key takeaways
  • Fig. 45 Small molecule innovator API CDMO market: Therapeutic area movement analysis
  • Fig. 46 Cardiovascular diseases small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 47 Oncology small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 48 Respiratory disorders small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 49 Neurology small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 50 Metabolic disorders small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 51 Infectious diseases small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 52 Others small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 53 Regional market: Key takeaways
  • Fig. 54 Regional outlook, 2023 & 2030
  • Fig. 55 Regional outlook, 2023 & 2030
  • Fig. 56 North America small molecule innovator API CDMO market, 2018 - 2030 (USD Million)
  • Fig. 57 Key country dynamics
  • Fig. 58 U.S. small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Key country dynamics
  • Fig. 60 Canada small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Europe small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 Key country dynamics
  • Fig. 63 UK small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Key country dynamics
  • Fig. 65 Germany small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 Key country dynamics
  • Fig. 67 France small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Key country dynamics
  • Fig. 69 Italy small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Key country dynamics
  • Fig. 71 Spain small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 Key country dynamics
  • Fig. 73 Denmark small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 Key country dynamics
  • Fig. 75 Sweden small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Key country dynamics
  • Fig. 77 Norway small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 Rest of Europe small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 MEA small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 80 Key country dynamics
  • Fig. 81 South Africa small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 82 Key country dynamics
  • Fig. 83 Saudi Arabia small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 84 Key country dynamics
  • Fig. 85 Clinical trial authorization process UAE
  • Fig. 86 UAE small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 87 Key country dynamics
  • Fig. 88 Regulatory framework: South Africa
  • Fig. 89 Kuwait small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 90 Key country dynamics
  • Fig. 91 Israel small molecule innovator API CDMO estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 92 Rest of Europe small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 93 Asia Pacific small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 94 Key country dynamics
  • Fig. 95 China small molecule innovator API CDMO estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 96 Key country dynamics
  • Fig. 97 Regulatory bodies in India involved in pharmaceutical regulations
  • Fig. 98 India small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 99 Key country dynamics
  • Fig. 100 Clinical trial authorization process in Japan
  • Fig. 101 Clinical research of medical products in Japan
  • Fig. 102 Japan small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 103 Key country dynamics
  • Fig. 104 Australia small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 105 Key country dynamics
  • Fig. 106 Clinical trial approval process in South Korea
  • Fig. 107 South Korea small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 108 Key country dynamics
  • Fig. 109 Thailand small molecule innovator API CDMO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 110 Key country dynamics
  • Fig. 111 Taiwan small molecule innovator API CDMO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 112 Rest of APAC small molecule innovator API CDMO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 113 Key country dynamics
  • Fig. 114 Brazil small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 115 Key country dynamics
  • Fig. 116 Mexico small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 117 Key country dynamics
  • Fig. 118 Argentina pharmaceuticals registration details
  • Fig. 119 Argentina small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 120 Market participant categorization
  • Fig. 121 Heat map analysis
  • Fig. 122 Market participant categorization